Jian Zhou
Jian Zhou
Contributor, The Yuan

Jian Zhou formerly served as a data analyst at consulting company Kantar media CIC under WPP and a data analyst for CBNData. Over six years of industry experience, Jian has become an expert in Big Data analysis (SQL, Hadoop, Hive), statistical analysis, data mining, predictive modeling, and medical industry intelligence analysis. 

Combination of radiopharmaceuticals and AI has become a clear trend
CIC and The Yuan have jointly released their report on the Development Trend of Integrated Nuclear Medicine Diagnosis and Treatment to chart the future course of integrated nuclear medicine diagnosis and treatment, a new field that augurs great breakthroughs in fighting disease.
Sophia Wang, Jian Zhou  |  Jun 15, 2023
AI in nuclear medicine: harnessing the power of radiation to do good
Radioactive substances are normally harmful, but nuclear medicine aims to take that destructive power and use it to treat - or at least diagnose - diseases. Efforts to combine this with AI to treat diseases like cancer in new and more effective ways continue to advance, and so the globally leading online AI community The Yuan has partnered with the world-renowned think tank Deep Pharma Intelligence and the world leading nuclear medicine company Evomics to put together this report, which takes an in-depth look at the latest AI applications in nuclear medicine and radiology and what the future of AI in these fields might look like, as well as the specific steps being taken by the private sector and governments around the world to help drive this development.
Jian Zhou, Jack Kotin  |  Mar 01, 2023
Pioneering Report Maps AI+RWS Sector, Forecasts 40% Yearly Growth in China
Domain knowledge
A pioneering new report offers an overview of pharma RWS/RCT industry developments in 2020-2021, Asia’s RWS market size, trends there and in China - where it predicts 40 percent yearly growth - and showcases Asian RWS industry leaders. It discusses use of virtual Twin Studies, GWAS, Pharmacovigilance and AI, and explores RWS and AI used in diagnostics, biomarkers, image analysis, disease prevention, and Big Data. It then cites the challenges and opportunities faced by AI-driven WRS and lists governmental regulations on RWS and Big Data in Asia.
Jian Zhou, Ben Armour  |  Oct 29, 2021